Evidence map›Paper›PMID 33516656›Full record

ArticleCancer treatment and research communications2021

AR-V7 biomarker testing for primary prostate cancer: The ongoing challenge of analytical validation and clinical qualification.

Adam G Sowalsky, Adam Sharp, Shana Y Trostel, Johann S de Bono, Stephen R Plymate

Open access · goldAbstract readLetterComment
PubMed Full text at PMC Publisher
In one paragraph

Article in Cancer treatment and research communications, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
0.4field-weighted citation impact, top 33% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed, 3 citations in OpenAlex.

  1. Assessment of Androgen Receptor Splice Variant-7 as a Biomarker of Clinical Response in Castration-Sensitive Prostate Cancer.Clinical cancer research : an official journal of the American Association for Cancer Research · 2022
    Article
4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

5 authors at 4 institutions in 2 countries.

Adam G SowalskyLaboratory of Genitourinary Cancer Pathogenesis, National Cancer Institute, NIH, Bethesda, MD, United States. Electronic address: adam.sowalsky@nih.gov.
Adam SharpThe Institute of Cancer Research, London, United Kingdom; The Royal Marsden, London, United Kingdom.
Shana Y TrostelLaboratory of Genitourinary Cancer Pathogenesis, National Cancer Institute, NIH, Bethesda, MD, United States.
Johann S de BonoThe Institute of Cancer Research, London, United Kingdom; The Royal Marsden, London, United Kingdom.
Stephen R PlymateDepartment of Medicine, University of Washington, Seattle, WA, United States; Puget Sound VA Health Care System, Geriatric Research Education and Clinical Center, Seattle, WA, United States.
National Cancer Institute · USGeriatric Research Education and Clinical Center · USInstitute of Cancer Research · GBRoyal Marsden Hospital · GB

Funding

Mechanisms of resistance to treatment in aggressive prostate cancersZIABC011838 · NCI · DIVISION OF BASIC SCIENCES - NCI · PI SOWALSKY, ADAM · 2018 to 2025
$5.7M
Intramural NIH HHS Z99 CA999999Intramural NIH HHS ZIA BC011838Medical Research Council MR/M018318/1Medical Research Council MR/M018618/1
6 · The paper itself

Abstract

PubMed holds no abstract for this paper.

Indexed as

Prostatic Neoplasms, Castration-ResistantBiomarkersHumansLongitudinal StudiesMalePhenylthiohydantoinBiomarkersPhenylthiohydantoin

Identifiers

PMID33516656
PMCPMC8114102
OpenAlexW3092000359

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.